|Day Low/High||89.40 / 93.67|
|52 Wk Low/High||90.95 / 232.76|
Here is where aggressive traders could go long the cancer therapy name.
NVCR gapped sharply higher today, in one of the most impressive upside gaps we have seen in a long time. Check it out.
Our latest analysis and trading strategy on NVCR.
Let's check out the charts and indicators again to see what has changed in the past month.
Prices have doubled in just three months.
Plus, the chart of Novocure Limited is a real attention-grabber while the chart of Apple bears watching.
These names combine healthcare research with state-of-the art technology.
Let's review the charts and indicators of NVCR.
The oncology company has had a strong run and all the technical signals indicate the move higher isn't over.
Let's look at the charts and indicators in addition to following the fundamentals.
Here we go folks, a sampling of this morning's upgrades, downgrades and initiations. I'll be back with some thought on these after I get another cup of my morning fuel (coffee). Upgrades Sprint by UBS from Neutral to Buy with a $10 price target Res...
The oncology company already has risen significantly this year, but its charts indicate the rally could continue.
Oncology firm released results that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.
The normal chart patterns don't operate like they have in the past.
Here's what I'm trading today amid the 'flat with a positive tone' action.
Coming off a brutal first quarter, Bill Ackman's hedge fund announced the loss of a key strategist.
Cancer treatment company NovoCure (NVCR) debuted as a public company trading on the Nasdaq on Friday, despite weakness seen in the IPO market so far this year.
U.S. stocks opened lower Friday as the Labor Department stunned Wall Street with a majorly disappointing September jobs report.